DOP33: Single-cell analysis identifies pathological fibroblasts as a new therapeutic target to prevent intestinal fibrosis in Crohn's disease.ECCO’23 CopenhagenYear: 2023
Authors: Ke, B.J.(1);Abdurahiman, S.(1);Biscu, F.(1);Verstockt, S.(1);Verstockt, B.(2);de Hertogh, G.(3);Vermeire, S.(2);Matteoli, G.(1)*;
(1)KU Leuven, Translational Research Center for Gastrointestinal Disorders- Department of Chronic Diseases and Metabolism, Leuven, Belgium;(2)University Hospitals Leuven, Department of Gastroenterology and Hepatology, Leuven, Belgium;(3)University Hospitals Leuven, Department of Pathology, Leuven, Belgium;
DOP34: Human MD2 deficiency - an inborn error of immunity predisposing to early onset Inflammatory Bowel DiseaseECCO’23 CopenhagenYear: 2023
Authors: Li, Y.(1)*;Yu, Z.(1);Schenk, M.(1);Lagovsky, I.(2);Illig, D.(1);Walz, C.(3);Rohlfs, M.(1);Conca, R.(1);Muise, A.(4);Snapper, S.(5);Uhlig, H.(6);Garty, B.(7);Klein, C.(1);Kotlarz, D.(1);
(1)Dr. von Hauner Children's Hospital- Ludwig-Maximilians-Universität LMU, Department of Pediatrics, Munich, Germany;(2)Rabin Medical Center and Sackler School of Medicine, Felsenstein Medical Research Center, Tel Aviv, Israel;(3)Faculty of Medicine- LMU Munich, Institute of Pathology, Munich, Germany;(4)Hospital for Sick Children, SickKids Inflammatory Bowel Disease Center, Toronto, Canada;(5)Boston Children's Hospital, Division of Gastroenterology- Hepatology and Nutrition, Boston, United States;(6)University of Oxford, Translational Gastroenterology Unit and Department of Pediatrics- and Biomedical Research Centre, Oxford, United Kingdom;(7)Tel Aviv University, Sackler School of Medicine, Tel-Aviv, Israel;
DOP35: High-fat diet reduces gut microbiota-derived metabolite indole-acetic acid and aggravates colitisECCO’23 CopenhagenYear: 2023
Authors: Li, M.(1)*;Dong, Y.(1);Zhang, K.(1);Ma, J.(1);He, L.(1);Wei, J.(1);Jiang, J.(1);Zhao, Q.(1);Zhao, Q.(1);Cao, H.(1);
(1)Tianjin Medical University General Hospital, Department of Gastroenterology and Hepatology, Tianjin, China;
DOP36: Vedolizumab-treated IBD patients show an increased gut microbial diversity associated with a specific serum metabolic signatureECCO’23 CopenhagenYear: 2023
Authors: Pisani, L.F.(1,2)*;Crespi, G.(3,4);Mellai, M.(4,5);Flavio, C.(6,7);Annunziata, M.L.(8);Manfredi, M.(4,9);Luca, P.(10,11);Porta, C.(3,4);
(1)University of Milano-Bicocca, Department of Biotechnology and Biosciences BtBs, Milan, Italy;(2)IRCCS Policlinico San Donato, Gastroenterology and Endoscopy Unit, San Donato Milanese, Italy;(3)University of Piemonte Orientale, Department of Pharmaceutical Sciences, Novara, Italy;(4)University of Piemonte Orientale, Center for Translational Research on Autoimmune and Allergic Diseases, Novara, Italy;(5)University of Piemonte Orientale, Department of Health Sciences, Novara, Italy;(6)University of MIlan, Department of Medical-Surgical Physiopathology and Transplantation, Milan, Italy;(7)Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico di Milano, Gastroenterology end endoscopy unit, Milan, Italy;(8)IRCCS Policlinico San Donato, Gastreoenterology and Endoscopy Unit, San Donato Milanese, Italy;(9)University of Piemonte Orientale, Department of Translational Medicine, Novara, Italy;(10)University of Milan, Department of Health Sciences, Milan, Italy;(11)ASST Santi Paolo e Carlo, Gastroenterology and Liver Unit, Milan, Italy;
DOP37: Efficacy and safety of 3 years of continuous ozanimod treatment: an interim analysis of the True North open-label extension studyECCO’23 CopenhagenYear: 2023
Authors: Danese, S.(1)*;Abreu, M.T.(2);Wolf, D.C.(3);Canavan, J.B.(4);Jain, A.(4);Wu, H.(4);Petersen, A.(4);Charles, L.(4);Panaccione, R.(5);Afzali, A.(6);
(1)IRCCS Ospedale San Raffaele and University Vita-Salute San Raffaele, Head Gastroenterology and Gastrointestinal Endoscopy Unit, Milan, Italy;(2)University of Miami Miller School of Medicine, Gastroenterology Division, Miami, United States;(3)Atlanta Gastroenterology Associates LLC, IBD Research, Atlanta, United States;(4)Bristol Myers Squibb, Clinical Research, Princeton, United States;(5)Inflammatory Bowel Disease Clinic, IBD Research, Alberta, Canada;(6)University of Cincinnati College of Medicine, Gastroenterology, Cincinnati, United States;
DOP38: Upadacitinib Therapy Reduces Crohn's Disease Symptoms Within the First Week of Induction TherapyECCO’23 CopenhagenYear: 2023
Authors: Colombel, J.F.(1)*;Hisamatsu, T.(2);Bresso , F.(3);Thin, L.(4);Parra, R.(5);Ford, S.(6);Remple, V.(6);Lacerda, A.P.(6);Hecht, P.(6);Mallick, M.(6);Garrison, A.(6);Regueiro, M.(7);
(1)Icahn School of Medicine at Mount Sinai, Gastroenterology, New York, United States;(2)Kyorin University School of Medicine, Gastroenterology, Mitaka, Japan;(3)Karolinska University Hospital, Department of Gastroenterology- Dermatology- and Rheumatology, Stockholm, Sweden;(4)Fiona Stanley Hospital, Gestroenterology, Perth, Australia;(5)Ribeirão Preto Medical School- University of São Paulo, Department of Gastroenterology, Sao Paulo, Brazil;(6)AbbVie, none, North Chicago, United States;(7)Cleveland Clinic Foundation, Department of Gastroenterology and Hepatology, Cleveland, United States;
DOP39: Endoscopic, histologic, and combined outcomes with reinitiation of ozanimod after temporary discontinuation: 2-year interim analysis of the True North open-label extension studyECCO’23 CopenhagenYear: 2023
Authors: Vermeire, S.(1)*;Dignass, A.(2);Colombel, J.F.(3);Jain, A.(4);Canavan, J.B.(4);Wu, H.(4);Lawlor, G.(4);Osterman, M.T.(4);Rubin, D.T.(5);Regueiro, M.(6);
(1)University of Leuven, Chronic Diseases and Metabolism, Leuven, United States;(2)Agaplesion Markus Hospital- Goethe University, Medicine, Frankfurt, Germany;(3)Icahn School of Medicine of Mount Sinai, Gastroenterology, New York, United States;(4)Bristol Myers Squibb, Clinical Research, Princeton, United States;(5)University of Chicago Medicine Inflammatory Bowel Disease Center, Gastroenterology, Chicago, United States;(6)Cleveland Clinic, Digestive Disease and Surgery Institute, Cleveland, United States;
DOP40: Corticosteroid discontinuation and clinical outcomes in patients with moderately to severely active Crohn's disease treated with upadacitinibECCO’23 CopenhagenYear: 2023
Authors: Dubinsky, M.C.(1)*;D'Haens, G.(2);Dewit, O.(3);Juillerat, P.(4);Panaccione, R.(5);Fujii, T.(6);Lacerda, A.P.(7);Dubcenco, E.(7);Anyanwu, S.(7);Doshi, C.(7);Mallick, M.(7);Garrison, A.(7);Liu, J.(7);Loftus Jr, E.V.(8);
(1)Icahn School of Medicine at Mount Sinai, Division of Pediatric Gastroenterology, New York, United States;(2)Amsterdam University Medical Center, Department of Gastroenterology and Hepatology, Amsterdam, Netherlands Antilles;(3)UCLouvain, Cliniques universitaires Saint-Luc, Brussels, Belgium;(4)Bern University Hospital, Clinic for Visceral Surgery and Medicine, Bern, Switzerland;(5)University of Calgary, Inflammatory Bowel Disease Unit, Calgary, Canada;(6)Tokyo Medical and Dental University, Department of Gastroenterology and Hepatology, Tokyo, Japan;(7)AbbVie Inc., Research and Development, North Chicago, United States;(8)Mayo Clinic School of Medicine and Science, Division of Gastroenterology and Hepatology, Rochester, United States;
DOP41: Achievement of corticosteroid-free clinical endpoints in subjects with ulcerative colitis: an analysis of the phase 3 ELEVATE UC 52 trialECCO’23 CopenhagenYear: 2023
Authors: Sands, B.E.(1);Rubin, D.T.(2);Panés, J.(3);Gecse, K.B.(4);Leung, Y.(5);Goetsch, M.(6);Wang, W.(7);Shan, K.(8);Woolcott, J.(9);Smith, C.C.(9);Wosik, K.(10);Schreiber, S.W.(11)*;
(1)Dr. Henry D. Janowitz Division of Gastroenterology- Icahn School of Medicine at Mount Sinai, Gastroenterology, New York- New York, United States;(2)University of Chicago Medicine, Section of Gastroenterology- Hepatology and Nutrition, Chicago- Illinois, United States;(3)Hospital Clínic de Barcelona- IDIBAPS- CIBERehd, Gastroenterology, Barcelona, Spain;(4)Amsterdam UMC, Gastroenterology, Amsterdam, The Netherlands;(5)University of British Columbia, Gastroenterology, Vancouver- British Columbia, Canada;(6)Pfizer AG, Global Clinical Development, Zurich, Switzerland;(7)Pfizer Inc, Biostatistics, Collegeville- Pennsylvania, United States;(8)Pfizer Inc, Global Project Development- Inflammation & Immunology, New York- New York, United States;(9)Pfizer Inc, Global Medical Affairs- Gastroenterology, Collegeville- Pennsylvania, United States;(10)Pfizer Inc, Global Medical Affairs- Gastroenterology, Kirkland, Canada;(11)University Hospital Schleswig-Holstein- Department Internal Medicine I- Kiel University, Internal Medicine, Kiel, Germany;
DOP42: Efficacy of etrasimod on symptomatic relief in patients with ulcerative colitis: an analysis of the phase 3 ELEVATE UC 52 and ELEVATE UC 12 trialsECCO’23 CopenhagenYear: 2023
Authors: Chaparro, M.(1)*;Armuzzi, A.(2);Irving, P.M.(3,4);Allez, M.(5);Dubinsky, M.C.(6);Sands, B.E.(7);Goetsch, M.(8);Wang, W.(9);Shan, K.(10);Woolcott, J.(11);Bartolome, L.(12);Wosik, K.(13);Panaccione, R.(14);
(1)Hospital Universitario de La Princesa- Instituto de Investigación Sanitaria Princesa IIS-Princesa- Universidad Autónoma de Madrid UAM- Centro de Investigación Biomédica en Red de Enfermedades Hepáticas y Digestivas CIBEREHD, Gastroenterology, Madrid, Spain;(2)IRCCS Humanitas Research Hospital- Rozzano, IBD Center, Milan, Italy;(3)Guy's and St Thomas' NHS Foundation Trust, Gastroenterology, London, United Kingdom;(4)King's College London, School of Immunology & Microbial Sciences, London, United Kingdom;(5)Hôpital Saint Louis- Université Paris, Gastroenterology, Diderot, France;(6)Icahn School of Medicine- Mount Sinai, Feinstein IBD Center, New York- New York, United States;(7)Icahn School of Medicine- Mount Sinai, Dr. Henry D. Janowitz Division of Gastroenterology, New York- New York, United States;(8)Pfizer AG, Global Clinical Development, Zurich, Switzerland;(9)Pfizer Inc, Biostatistics, Collegeville- Pennsylvania, United States;(10)Pfizer Inc, Biostatistics, New York- New York, United States;(11)Pfizer Inc, Global Medical Affairs- Gastroenterology, Collegeville- Pennsylvania, United States;(12)Pfizer Inc, Global Health Economics & Outcomes Research- Inflammation & Immunology, New York- New York, United States;(13)Pfizer Inc, Global Medical Affairs- Gastroenterology, Kirkland- Quebec, Canada;(14)University of Calgary, Inflammatory Bowel Disease Unit- Division of Gastroenterology and Hepatology, Calgary- Alberta, Canada;
DOP43: Extended induction in the True North OLE study: ozanimod efficacy in biologic-naive and biologic-experienced patientsECCO’23 CopenhagenYear: 2023
Authors: Dignass, A.(1)*;Regueiro, M.(2);Colombel, J.F.(3);Jain, A.(4);Canavan, J.B.(4);Wu, H.(4);Lawlor, G.(4);Osterman, M.T.(4);Vermeire, S.(5);Rubin, D.T.(6);
(1)Agaplesion Markus Hospital- Goethe University, Medicine, Frankfurt, Germany;(2)Cleveland Clinic, Digestive Disease and Surgery Institute, Cleveland, United States;(3)Icahn School of Medicine at Mount Sinai, Gastroenterology, New York, United States;(4)Bristol Myers Squibb, Clinical Research, Princeton, United States;(5)University Hospitals Leuven, Chronic Diseases and Metabolism, Leuven, Belgium;(6)The University of Chicago Medicine Inflammatory Bowel Disease, Gastroenterology, Chicago, United States;
DOP44: Tofacitinib versus corticosteroids for induction of remission in moderately active ulcerative colitis (ORCHID): A prospective randomized open-label pilot studyECCO’23 CopenhagenYear: 2023
Authors: SinghD.M., A.(1)*;Midha, V.(2);Mahajan, R.(1);Kaur, K.(3);Singh, D.(4);Sood, A.(1);
(1)Dayanand Medical College and Hospital, Gastroenterology, Ludhiana, India;(2)Dayanand Medical College and Hospital, Medicine, Ludhiana, India;(3)Dayanand Medical College and Hospital, Pharmacology, Ludhiana, India;(4)Dayanand Medical College and Hospital, Research and Development, Ludhiana, India;
DOP45: Predicting late responders to filgotinib in patients with moderately to severely active Ulcerative Colitis: A post hoc analysis of SELECTION and SELECTIONLTEECCO’23 CopenhagenYear: 2023
Authors: Matsuoka, K.(1)*;Löwenberg, M.(2);Fumery, M.(3);Takatori, Y.(4);Fujitani, Y.(4);Oortwijn, A.(5);Faes, M.(6);Jamoul, C.(6);Hibi, T.(7);
(1)Toho University Sakura Medical Center, Division of Gastroenterology and Hepatology- Department of Internal Medicine, Chiba, Japan;(2)University of Amsterdam, Department of Gastroenterology and Hepatology, Amsterdam, The Netherlands;(3)Amiens University Hospital, Department of Gastroenterology, Amiens, France;(4)Gilead Sciences, K.k., Tokyo, Japan;(5)Galapagos, Nv, Leiden, The Netherlands;(6)Galapagos, Nv, Mechelen, Belgium;(7)Kitasato University Kitasato Institute Hospital, Center for Advanced IBD Research and Treatment, Tokyo, Japan;
DOP46: Mucosal host-microbe interactions associate with clinical phenotypes in Inflammatory Bowel DiseaseECCO’23 CopenhagenYear: 2023
Authors: Bourgonje, A.(1)*;Hu, S.(1);Gacesa, R.(1);Jansen, B.H.(1);Björk, J.R.(1);Bangma, A.(1);Hidding, I.J.(1);van Dullemen, H.M.(1);Visschedijk, M.C.(1);Faber, K.N.(1);Dijkstra, G.(1);Harmsen, H.J.M.(2);Festen, E.A.M.(1);Vich Vila, A.(1);Spekhorst, L.M.(1);Weersma, R.K.(1);
(1)University of Groningen- University Medical Center Groningen, Gastroenterology and Hepatology, Groningen, The Netherlands;(2)University of Groningen- University Medical Center Groningen, Medical Microbiology, Groningen, The Netherlands;
DOP47: Gut microbiome contributes to the development of immune checkpoint inhibitor-related colitisECCO’23 CopenhagenYear: 2023
Authors: Liu, X.(1,2)*;Tang, H.(3);Zhou, Q.(1);Zeng, Y.(1,4);Lu, B.(1);Chen, M.(5);Xu, Y.(5);Wang, M.(5);Li, Y.(1);Tan, B.(1);Qian, J.(1);
(1)Peking Union Medical College Hospital- Peking Union Medical College & Chinese Academy of Medical Science, Department of Gastroenterology, Beijing, China;(2)Peking Union Medical College & Chinese Academy of Medical Science, Eight-year Medical Doctor Program, Beijing, China;(3)Peking Union Medical College Hospital- Peking Union Medical College & Chinese Academy of Medical Science, Department of Internal Medicine, Beijing, China;(4)Tsinghua University, School of Medicine, Beijing, China;(5)Peking Union Medical College Hospital- Peking Union Medical College & Chinese Academy of Medical Science, Department of Respiratory and Critical Care Medicine, Beijing, China;
DOP48: Key Anti-Inflammatory Faecalibacterium prausnitzii is Heterogeneous and Diverse in the East and West and in Health and Crohn's disease. The ENIGMA study.ECCO’23 CopenhagenYear: 2023
Authors: Teh, J.J.(1);Kang, S.(1);Leonard, A.(1);Zhang, J.(2,3,4);Hu, J.(2,3,4);Hamilton, A.L.(5,6);Wilson-O'Brien, A.(5,6);Trakman, G.L.(5,6);Lin, W.(2,3,4);Ching , J.(2,4);Sung, J.J.Y.(7);Yu, J.(2,4);Ng, S.C.(2,3,8);Kamm, M.A.(5,6)*;Morrison, M.(1);
(1)University of Queensland, Frazer Institute, Woolloongabba, Australia;(2)The Chinese University of Hong Kong, Department of Medicine and Therapeutics, Hong Kong, China;(3)Microbiota I-Center, MagIC, Hong Kong, China;(4)Li Ka Shing Institute of Health Sciences, State Key Laboratory of Digestive Disease, Hong Kong, China;(5)Saint Vincent's Hospital, Department of Gastroenterology, Melbourne, Australia;(6)University of Melbourne, Department of Medicine, Melbourne, Australia;(7)Nanyang Technological University, Lee Kong Chian School of Medicine, Singapore, Singapore;(8)The Chinese University of Hong Kong, Center for Gut Microbiota Research, Hong Kong, China;
DOP49: Metagenomic Characterisation of The Colonic Mucosa-Associated Microbiota Reveals Novel Microbes and Communities in Health and Crohn's disease. The ENIGMA study.ECCO’23 CopenhagenYear: 2023
Authors: Kang, S.(1);Teh, J.J.(1);Zhang, J.(2,3,4);Hu, J.(2,3,4);Hamilton, A.L.(5,6);Wilson-O'Brien, A.(5,6);Trakman, G.L.(5,6);Lin, W.(2,3,4);Ching, J.(2,4);Sung, J.J.Y.(7);Yu, J.(2,4);Ng, S.C.(2,3,8);Kamm, M.A.(5,6)*;Morrison, M.(1);
(1)University of Queensland, Frazer Institute, Woolloongabba, Australia;(2)The Chinese University of Hong Kong, Department of Medicine and Therapeutics, Hong Kong, China;(3)Microbiota I-Center, MagIC, Hong Kong, China;(4)Li Ka Shing Institute of Health Sciences, State Key Laboratory of Digestive Disease, Hong Kong, China;(5)Saint Vincent's Hospital, Department of Gastroenterology, Melbourne, Australia;(6)University of Melbourne, Department of Medicine, Melbourne, Australia;(7)Nanyang Technological University, Lee Kong Chian School of Medicine, Singapore, Singapore;(8)The Chinese University of Hong Kong, Center for Gut Microbiota Research, Hong Kong, China;
DOP50: Impact of Inflammatory Bowel Disease associated dysbiosis on bacterial quorum sensing mediated by Acyl-homoserine Lactone in human gut microbiotaECCO’23 CopenhagenYear: 2023
Authors: Grellier, N.(1,2,3)*;Suzuki, M.(4);Brot, L.(1);Rodrigues, A.(4);Humbert, L.(1);Escoubeyrou, K.(4);Rainteau, D.(1);Grill, J.P.(1);Lami, R.(4);Seksik, P.(1,3);
(1)Sorbonne Université, Saint-Antoine Research Center, Paris, France;(2)Centre Hospitalier Universitaire de Poitiers, Hepato-gastroenterology department, Poitiers, France;(3)Saint-Antoine hospital, Department of Gastroenterology, Paris, France;(4)Sorbonne Université, Laboratoire de Biodiversité et Biotechnologies Microbiennes, Banyuls-sur-mer, France;
DOP51: Mucosa-associated microbial signatures associate with objective response prior to the start of anti-TNFα but not vedolizumab or ustekinumab in Crohn's disease patientsECCO’23 CopenhagenYear: 2023
Authors: HagemanMD, I.(1)*;Joustra, V.(2);Zafeiropoulou , K.(1);Davids, M.(3);Hakvoort, T.(1);Probert, F.(4);Satsangi, J.(5);D'Haens, G.(2);De Jonge, W.(1);
(1)Tytgat Institute for Liver and Intestinal Research, Department of Gastroenterology & Hepatology, Amsterdam, The Netherlands;(2)Amsterdam UMC, Department of Gastroenterology and Hepatology, Amsterdam, The Netherlands;(3)Amsterdam UMC, Laboratory of Experimental Vascular Medicine, Amsterdam, The Netherlands;(4)Chemistry Research Laboratory- Oxford University, Department of Chemistry, Oxford, United Kingdom;(5)Translational Gastroenterology Unit- NIHR Oxford Biomedical Research Centre, Oxford University Hospitals NHS Foundation Trust- John Radcliffe Hospital, Oxford, United Kingdom;On behalf of the EPIC-Pioneer consortium
DOP52: The faecal bacterial and fungal microbiome of newly-diagnosed, treatment naïve children with Crohn's disease and the modifying effects of exclusive enteral nutrition and re-introduction of habitual dietECCO’23 CopenhagenYear: 2023
Authors: Gerasimidis, K.(1)*;Nichols, B.(1);Papadopoulou, R.(1);Ijaz, U.(2);Rajendran, R.(3);Quince, C.(4);Russell, R.K.(5);Hansen, R.(6);Ramage, G.(3);
(1)University of Glasgow, Human Nutrition, Glasgow, United Kingdom;(2)University of Glasgow, School of Engineering, Glasgow, United Kingdom;(3)University of Glasgow, Dental School, Glasgow, United Kingdom;(4)Earlham Institute, Organisms and Ecosystems, Norwich, United Kingdom;(5)Royal Hospital for Sick Children and Young People, Paediatric Gastroenterology- Hepatology and Nutrition, Edinburgh, United Kingdom;(6)Royal Hospital for Children, Paediatric Gastroenterology- Hepatology and Nutrition, Glasgow, United Kingdom;
